Truist Financial’s CytomX Therapeutics CTMX Stock Holding History

Truist Financial’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,500	Closed	-$12.6K	–	2780
2025 Q3	$12.6K	Buy	+12,500	New	+$28.2K	﹤0.01%	2706

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Truist Financial's CTMX Position: Q4 2025 in Review

Truist Financial sold out of CytomX Therapeutics (CTMX) in Q4 2025, closing a stake of 12,500 shares — an estimated $12.6K sold.

Truist Financial first reported a position in CTMX in Q3 2025 and held it in 1 quarter. The position peaked at $12.6K in Q3 2025. 122 funds tracked by Wall St. Rank hold CTMX as of Q4 2025.

Truist Financial reported no remaining CytomX Therapeutics position as of Q4 2025 after selling out during the quarter.
Truist Financial sold 12,500 CytomX Therapeutics shares in Q4 2025, an estimated $12.6K.
Truist Financial first reported a position in CytomX Therapeutics in Q3 2025 and held it in 1 quarter.
Truist Financial's CytomX Therapeutics position peaked at $12.6K in Q3 2025.
122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2025.

Based on Truist Financial's 13F filing for Q4 2025, filed 2 Feb 2026.